Login Get Started
Browse
Shares
Healthcare
Biotechnology & Medical Research
BioXcel Therapeutics Inc
BioXcel Therapeutics Inc logo

BTAI - BioXcel Therapeutics Inc Share News

$45.2 2.2  5.2%

Last Trade - 05/03/21

Sector
Healthcare
RiskRating
Speculative
Size
Mid Cap
Style
Sucker Stock
Market Cap £795.8m
Enterprise Value £627.1m
Revenue £n/a
Position in Universe 2702nd / 6651
Quality
Value
Momentum
StockRank™
StockReport™
Tools
Compare with... Run through checklist
Accounts
Balance sheet Income statement Cashflow statement Dividend summary
Charts News Discussions BTAI Dividends
All News
All News Reuters News Company Announcements
U.S. RESEARCH ROUNDUP-American Eagle Outfitters, Caterpillar, Provident Financial Services
Fri 7:43am News
BioXcel Therapeutics to Host Fourth Quarter and Full Year 2020 Operating and Financial Results Conference Call and Webcast
Thu 12:00pm News
BRIEF-Bioxcel Therapeutics Provides Update On BXCl501 Program For Acute Treatment Of Dementia Related Agitation
Wed 12:04pm News
BioXcel Therapeutics Provides Update on its BXCL501 Program for the Acute Treatment of Dementia Related Agitation
Wed 12:00pm News
BRIEF-BioXcel Therapeutics Appoints June Bray To Board Of Directors
Mon 12:52pm News
BioXcel Therapeutics Appoints June Bray to Board of Directors
Mon 12:00pm News
BRIEF-Bioxcel Therapeutics Announces Initiation Of Phase 2 Placidity Trial Of Bxcl501 For The Treatment Of Delirium Related Agitation
25th Feb News
BioXcel Therapeutics Announces Initiation of Phase 2 PLACIDITY Trial of BXCL501 for the Treatment of Delirium Related Agitation
25th Feb News
BioXcel Therapeutics Appoints Javier Rodriguez as Chief Legal Officer and Corporate Secretary
23rd Feb News
BioXcel Therapeutics to Host Virtual Key Opinion Leader Event to Highlight BXCL501 as a Potential Treatment for Agitation and Opioid Withdrawal Symptoms
12th Feb News
BioXcel Therapeutics to Present an Update from its Ongoing Trial of BXCL701 in Aggressive Forms of Prostate Cancer at the 2021 ASCO Genitourinary Cancers Symposium
4th Feb News
BRIEF-Bioxcel Therapeutics Inc - Had Received Notice That FDA Has Granted Orphan Drug Designation For Company S Product Candidate, Bxcl701
28th Jan News
U.S. RESEARCH ROUNDUP-Arista Networks, Coresite Realty, Ormat Technologies
6th Jan News
BUZZ-BioXcel: Jumps after treatment reduces agitation in Dementia patients
5th Jan News
BRIEF-Bioxcel Therapeutics Announces Bxcl501 Met The Primary And All Secondary Endpoints In The Tranquility Phase 1B/2 Study For The Acute Treatment Of Agitation In Dementia, Including Alzheimer’S Disease
5th Jan News
BioXcel Therapeutics Announces BXCL501 Met the Primary and All Secondary Endpoints in the TRANQUILITY Phase 1b/2 Study for the Acute Treatment of Agitation in Dementia, including Alzheimer’s Disease
5th Jan News
BioXcel Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
17th Dec '20 News
BRIEF-BioXcel Therapeutics Announces Grant From U.S. DOD To Evaluate BXCl501 In Patients Suffering From PTSD
7th Dec '20 News
BioXcel Therapeutics Announces Grant by U.S. Department of Defense to Evaluate BXCL501 in Patients Suffering from PTSD
7th Dec '20 News
U.S. RESEARCH ROUNDUP- Arista Networks, Casper Sleep, G1 Therapeutics
18th Nov '20 News
© Stockopedia 2021, Refinitiv, Share Data Services.
Youtube Instagram RSS
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.